Last reviewed · How we verify

Self-adhesive resin

Aga Khan University · Phase 3 active Small molecule ✓ Verified May 2026

Self-adhesive resin is a Small molecule drug developed by Aga Khan University. It is currently in Phase 3 development for Dental restorations and bonding applications. Also known as: Seal and Protect, Dentsply.

A self-adhesive resin formulation that bonds to dental or oral surfaces to provide mechanical retention and therapeutic delivery.

Self-adhesive resin is used in dental applications, including direct composite restorations, to treat conditions such as tooth diseases, dental leakage, and gingival and periodontal disease. The resin is available under various trade names, including Futurabond, and is used in clinical trials to compare its performance with other adhesives.

Likelihood of approval
58.3% vs 58.3% industry baseline
If approved by FDA: likely 2028–2030
Steps remaining: NDA/BLA submission
Confidence: High
Why this estimate
  • Baseline phase 3 → approval rate +58.3pp
    Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2028–2030
EMA EU 2029–2031 +0.7 yr
MHRA GB 2029–2031 +0.7 yr
Health Canada CA 2029–2032 +0.9 yr
TGA AU 2029–2032 +1.2 yr
PMDA JP 2029–2032 +1.5 yr
NMPA CN 2030–2033 +2.3 yr
MFDS KR 2029–2032 +1.4 yr
CDSCO IN 2029–2033 +1.8 yr
ANVISA BR 2030–2033 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic nameSelf-adhesive resin
Also known asSeal and Protect, Dentsply
SponsorAga Khan University
ModalitySmall molecule
Therapeutic areaDentistry
PhasePhase 3

Mechanism of action

Self-adhesive resins are dental materials that chemically bond to tooth structure and restorative surfaces without requiring separate adhesive application. They typically contain functional monomers that interact with hydroxyapatite and collagen in tooth structure, creating a micromechanical and chemical bond while simultaneously setting through polymerization.

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Self-adhesive resin

What is Self-adhesive resin?

Self-adhesive resin is a Small molecule drug developed by Aga Khan University, indicated for Dental restorations and bonding applications.

How does Self-adhesive resin work?

A self-adhesive resin formulation that bonds to dental or oral surfaces to provide mechanical retention and therapeutic delivery.

What is Self-adhesive resin used for?

Self-adhesive resin is indicated for Dental restorations and bonding applications.

Who makes Self-adhesive resin?

Self-adhesive resin is developed by Aga Khan University (see full Aga Khan University pipeline at /company/aga-khan-university).

Is Self-adhesive resin also known as anything else?

Self-adhesive resin is also known as Seal and Protect, Dentsply.

What development phase is Self-adhesive resin in?

Self-adhesive resin is in Phase 3.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing